Recent Updates
Recently added Catalysts
CMPX Positive Sentiment Score: 70/100

Compass Therapeutics to Participate in Upcoming Investor Events

Key Takeaway: Compass Therapeutics, Inc. (CMPX), a clinical-stage biotechnology company, has announced its participation in two upcoming investor events in June 2023. The first event is the Jefferies Global Healthcare Conference in New York, where the company will give a presentation on June 8. Following that, it will participate in a panel discussion at the World Medical Innovation Forum in Boston on June 13, focusing on advances in cancer biologics. These events are pivotal for investor engagement and corporate visibility.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Therapeutics is actively engaging with investors at multiple events.
  • Participation at notable conferences like the Jefferies Global Healthcare Conference indicates company confidence.
  • The company's focus on innovative therapeutic approaches may generate investor interest.

Full Press Release Details

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June 2023.
Details are as follows:
Jefferies Global Healthcare Conference
Location: New York, NY
Format: Presentation
Date: Thursday, June 8
World Medical Innovation Forum hosted by Mass General Brigham Innovation and Bank of America
Location: Boston, MA
Format: Panel: The Disruptors: The Biologic Revolution in Cancer Continues
Date: Tuesday, June 13
Time: 8:30-9:30 AM ET
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Anna Gifford, Communications Manager

Frequently Asked Questions

When is Compass Therapeutics presenting at the Jefferies Conference?

Compass Therapeutics will present at the Jefferies Global Healthcare Conference on June 8, 2023.

What is the focus of Compass Therapeutics?

Compass Therapeutics specializes in developing antibody-based therapeutics for oncology.

What event will Compass participate in on June 13?

On June 13, Compass will participate in a panel at the World Medical Innovation Forum.

Where is Compass Therapeutics headquartered?

Compass Therapeutics is headquartered in Boston, Massachusetts.

How does Compass Therapeutics target tumors?

Compass targets tumors by modulating angiogenesis and enhancing immune responses.

Last updated: Jun 1, 2023